Resultados da busca - Benjamin Engelhardt

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials por Elena Muensterman, Benjamin Engelhardt, Sathej Gopalakrishnan, Jaclyn K. Anderson, Mohamed‐Eslam F. Mohamed

Obter o texto integral

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine por Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing

Obter o texto integral

Population Pharmacokinetics and Exposure‐Response Analyses for Telisotuzumab Vedotin in Patients With c‐Met Protein Overexpressing Tumors por Heiko Babel, Priya Brunsdon, Benjamin Engelhardt, Vanessa Schmitt, Christine Ratajczak, Sven Mensing, Rajeev M. Menon, Apurvasena Parikh

Obter o texto integral

Semi‐Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With Myelofibrosis por Akshanth R. Polepally, Aline Goebel, Maulik Patel, Carla Biesdorf, Jalaja Potluri, Rajeev M. Menon, Sven Mensing, Benjamin Engelhardt

Obter o texto integral

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181) por John Powderly, Alexander Spira, Shunsuke Kondo, Toshihiko Doi, Jason J. Luke, Drew Rasco, Bo Gao, Minna Tanner, Philippe A. Cassier, Anas Gazzah, Antoine Italiano, Diego Tosi, Daniel E. Afar, Apurvasena Parikh, Benjamin Engelhardt, Stefan Englert, Stacie L. Lambert, Sreeneeranj Kasichayanula, Sven Mensing, Rajeev Menon, Gregory Vosganian, Anthony Tolcher

Obter o texto integral